ReviewNature reviews. Rheumatology2015
Management of juvenile idiopathic arthritis: hitting the target.
Review in Nature reviews. Rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.Annals of the rheumatic diseases · 2025Guideline
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.Annals of the rheumatic diseases · 2024Guideline
- Methotrexate for juvenile idiopathic arthritis.The Cochrane database of systematic reviews · 2024Pooled it
- Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.Pediatric rheumatology online journal · 2018Guideline
- Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?Arthritis research & therapy · 2016Pooled it
- Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow up.Pediatric rheumatology online journal · 2023Trial
- Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.Pediatric rheumatology online journal · 2022Trial
- Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.Annals of the rheumatic diseases · 2018Trial
- A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.Pediatric rheumatology online journal · 2017Trial
- Adopting treat-to-target in paediatric rheumatic diseases.Nature reviews. Rheumatology · 2026Article
- Referral, treatment patterns and change in quality of life in the first 12 months in children and young people with juvenile idiopathic arthritis: an analysis of the association with ethnicity and socioeconomic position using data from a cohort study.Rheumatology (Oxford, England) · 2026Article
- Morning stiffness duration is associated with physician active joint count in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2026Observational
- Application of a novel Musculoskeletal Ultrasound Sum Score (MUSS) in the follow-up of patients with juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2026Article
- Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea.Journal of rheumatic diseases · 2026Article
- tRF-30-FP18LPMBQ4NK in Systemic Juvenile Idiopathic Arthritis: A Promising Diagnostic and Disease Activity Biomarker.Annals of the New York Academy of Sciences · 2026Article
- A stratified approach to juvenile idiopathic arthritis: leveraging machine learning to uncover subgroups of patients following treatment with etanercept.Rheumatology advances in practice · 2026Article
- The association between ethnicity, socioeconomic position and outcomes following initiation of methotrexate in juvenile idiopathic arthritis.EULAR rheumatology open · 2025Article
- Children's experiences of a support program during their first year with juvenile idiopathic arthritis : - Insights from qualitative interviews.Pediatric rheumatology online journal · 2025Article
- Population-Based Big Data Analysis on Disease Patterns in Patients Identified With Juvenile Idiopathic Arthritis Using National Claims Data.Journal of Korean medical science · 2025Article
- A narrative review of multidisciplinary rehabilitation in juvenile idiopathic arthritis.Clinical rheumatology · 2025Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of juvenile idiopathic arthritis (JIA) is evolving. The growing number of effective drugs has led to successful treatment and prevention of long-term sequelae in most patients. Although patients with JIA frequently achieve lasting clinical remission, sustained remission off medication is still elusive for most. Treatment approaches vary substantially among paediatric rheumatologists owing to the inherent heterogeneity of JIA and, until recently, to the lack of accepted and well-evidenced guidelines. Furthermore, many pertinent questions related to patient management remain unanswered, in particular regarding treatment targets, and selection, intensity and sequence of initiation or withdrawal of therapy. Existing JIA guidelines and recommendations do not specify treat-to-target or tight control strategies, in contrast to adult rheumatology in which these approaches have been successful. The concepts of window of opportunity (early treatment to improve long-term outcomes) and immunological remission (abrogation of subclinical disease activity) are also fundamental when defining treatment methodologies. This Review explores the application of these concepts to JIA and their possible contribution to the development of future clinical guidelines or consensus treatment protocols. The article also discusses how diverse forms of standardized, guideline-led care and personalized treatment can be combined into a targeted, patient-centred approach to optimize management strategies for patients with JIA.
Indexed as
Identifiers
25561365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.